Retrospective study of the efficacy and toxicity of lobaplatin-etoposide chemotherapy in small cell lung cancer
Retrospective study of the efficacy and toxicity of lobaplatin-etoposide chemotherapy in small cell lung cancer
复制标题
洛铂联合依托泊苷化疗治疗小细胞肺癌疗效及毒副反应的回顾性研究
DOI：
10.1111/1759-7714.12936
复制
发表时间：
2019
期刊：
影响因子：
2.9
通讯作者：
Qin Qiong
中科院分区：
文献类型：
--
作者：
Gu Liyan;Zhong Diansheng;Yu Tao;Tang Ping;Meng Fanlu;Qin Qiong
背景为评价洛铂-依托泊苷（EL）方案治疗小细胞肺癌（SCLC）的疗效和毒性，对2014年5月至2018年3月我科收治的50例SCLC患者的临床资料进行回顾性分析。入组未经治疗的SCLC患者，第1天静脉注射（IV）LBP 30 mg/m2，第1、2和3天静脉注射依托泊苷100 mg/m2。结果50例患者的中位总生存期和无进展生存期分别为11.67（范围：7.30-16.04）和6.8（范围：5.25-8.35）个月，总有效率为66%，疾病控制率为90%。最常见的药物相关的不良反应是白细胞减少症和中性粒细胞减少症，没有3/4级肝毒性或肾毒性被observed.ConclusionThese结果表明，LBP-含有化疗是有效的，耐受SCLC的反应和生存。
BackgroundA retrospective study was conducted to assess the efficacy and toxicity of lobaplatin‐etoposide (EL) chemotherapy for small cell lung cancer (SCLC).MethodsThe clinical data of 50 patients treated in our department from May 2014 to March 2018 were obtained. Untreated patients with SCLC administered LBP intravenously (IV) at 30 mg/m2on day 1 and etoposide IV at 100 mg/m2on days 1, 2, and 3 were enrolled. The treatment was cycled every 21 days.ResultsThe median overall and progression‐free survival rates of the 50 patients were 11.67 (range: 7.30–16.04) and 6.8 (range: 5.25–8.35) months, respectively, with an overall response rate of 66% and a disease control rate of 90%. The most frequent drug‐related adverse effects were leukopenia and neutropenia, and no grade 3/4 hepatotoxicity or nephrotoxicity was observed.ConclusionThese results indicate that LBP‐containing chemotherapy is effective and tolerable for SCLC in terms of response and survival.